Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (421-430 of 602) with videos related to

Pageof 61
Sort By:
American Journal of Hematology|February 10, 2017
Hematology patient reported symptom screen to assess quality of life for AL amyloidosisRahma Warsame, Shaji K Kumar, Morie A Gertz, et al.
Blood Advances|November 13, 2024
Retreatment of multiple myeloma with previously refractory drugsUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 24, 2019
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosisEli Muchtar, Angela Dispenzieri, Dragan Jevremovic, et al.
Leukemia|October 17, 2018
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapseSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
American Journal of Hematology|June 11, 2021
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Abdullah S Al Saleh, Shaji K Kumar, et al.
Pageof 61

Showing results (421-430 of 602) with videos related to

Sort By:
Pageof 61
American Journal of Hematology|February 10, 2017
Hematology patient reported symptom screen to assess quality of life for AL amyloidosisRahma Warsame, Shaji K Kumar, Morie A Gertz, et al.
Blood Advances|November 13, 2024
Retreatment of multiple myeloma with previously refractory drugsUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
Leukemia|February 24, 2021
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patientsAlissa Visram, Iuliana Vaxman, Abdullah S Al Saleh, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 24, 2019
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosisEli Muchtar, Angela Dispenzieri, Dragan Jevremovic, et al.
Leukemia|October 17, 2018
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapseSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
American Journal of Hematology|June 11, 2021
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trialsM Hasib Sidiqi, Abdullah S Al Saleh, Shaji K Kumar, et al.
Pageof 61